Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Smyth

Showing results (121-130 of 378) with videos related to

Pageof 38
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
The molecular pharmacology of doxorubicin in vivoJ Cummings, L Anderson, N Willmott, et al.
Biochemical Pharmacology|March 15, 1990
Relationship between reductive drug metabolism in tumour tissue of anthracyclines in microspherical form and anti-tumour activityN Willmott, J Cummings, E Marley, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1978
In vivo toxicity to lymphoid tissue by 2'-deoxycoformycinJ F Smyth, R C Young, D M Young
Science (New York, N.Y.)|October 16, 1992
Macroscopic quantum effects in nanometer-scale magnetsD D Awschalom, D P Divincenzo, J F Smyth
Seminars in Oncology|May 24, 2011
The interface between medical oncology and supportive and palliative cancer careDawn J Storey, Marie T Fallon, John F Smyth
The Journal of Pharmacy and Pharmacology|January 1, 1993
The long term stability of mechlorethamine hydrochloride (nitrogen mustard) ointment measured by HPLCJ Cummings, A MacLellan, S J Langdon, et al.
Analytical Biochemistry|September 25, 2001
High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cellsG Boyd, J F Smyth, D I Jodrell, et al.
Biochemical Pharmacology|June 22, 1993
Correlation between tumour drug disposition and the antitumour activity of doxorubicin-loaded microspheres: implications for the drugs' in vivo mechanism of actionJ Cummings, N Willmott, E C Marley, et al.
Anti-Cancer Drug Design|July 1, 1996
Characterization of the major metabolite of the novel topoisomerase I inhibitor NU/ICRF 505J Cummings, I Meikle, J S Macpherson, et al.
British Journal of Cancer|August 1, 1996
Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505I Meikle, J Cummings, J S Macpherson, et al.
Pageof 38

Showing results (121-130 of 378) with videos related to

Sort By:
Pageof 38
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
The molecular pharmacology of doxorubicin in vivoJ Cummings, L Anderson, N Willmott, et al.
Biochemical Pharmacology|March 15, 1990
Relationship between reductive drug metabolism in tumour tissue of anthracyclines in microspherical form and anti-tumour activityN Willmott, J Cummings, E Marley, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1978
In vivo toxicity to lymphoid tissue by 2'-deoxycoformycinJ F Smyth, R C Young, D M Young
Science (New York, N.Y.)|October 16, 1992
Macroscopic quantum effects in nanometer-scale magnetsD D Awschalom, D P Divincenzo, J F Smyth
Seminars in Oncology|May 24, 2011
The interface between medical oncology and supportive and palliative cancer careDawn J Storey, Marie T Fallon, John F Smyth
The Journal of Pharmacy and Pharmacology|January 1, 1993
The long term stability of mechlorethamine hydrochloride (nitrogen mustard) ointment measured by HPLCJ Cummings, A MacLellan, S J Langdon, et al.
Analytical Biochemistry|September 25, 2001
High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cellsG Boyd, J F Smyth, D I Jodrell, et al.
Biochemical Pharmacology|June 22, 1993
Correlation between tumour drug disposition and the antitumour activity of doxorubicin-loaded microspheres: implications for the drugs' in vivo mechanism of actionJ Cummings, N Willmott, E C Marley, et al.
Anti-Cancer Drug Design|July 1, 1996
Characterization of the major metabolite of the novel topoisomerase I inhibitor NU/ICRF 505J Cummings, I Meikle, J S Macpherson, et al.
British Journal of Cancer|August 1, 1996
Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505I Meikle, J Cummings, J S Macpherson, et al.
Pageof 38